Rescue of High Glucose Impairment of Cultured Human Osteoblasts Using Cinacalcet and Parathyroid Hormone
Calcified Tissue International · 2023
DOI: 10.1007/s00223-023-01062-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Calcified Tissue International, 2023. Verfasst von V A Shahen und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, 2006, Australia. Hauptthemen laut MEDLINE: Parathyroid Hormone, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Patients with type 2 diabetes mellitus (T2DM) experience a higher risk of fractures despite paradoxically exhibiting normal to high bone mineral density (BMD). This has drawn into question the applicability to T2DM of conventional fracture reduction treatments that aim to retain BMD. In a primary human osteoblast culture system, high glucose levels (25 mM) impaired cell proliferation and matrix mineralization compared to physiological glucose levels (5 mM). Treatment with parathyroid hormone (PTH, 10 nM), a bone anabolic agent, and cinacalcet (CN, 1 µM), a calcimimetic able to target the Ca 2+ -sensing receptor (CaSR), were tested for their effects on proliferation and differentiation. Strikingly, CN+PTH co-treatment was shown to promote cell growth and matrix mineralization under both physiological and high glucose conditions. CN+PTH reduced apoptosis by 0.9-fold/0.4-fold as measured by Caspase-3 activity assay, increased alkaline phosphatase (ALP) expression by 1.5-fold/twofold, increased the ratio of nuclear factor κ-B ligand (RANKL) to osteoprotegerin (OPG) by 2.1-fold/1.6-fold, and increased CaSR expression by 1.7-fold/4.6-fold (physiological glucose/high glucose). Collectively, these findings indicate a potential for CN+PTH combination therapy as a method to ameliorate the negative impact of chronic high blood glucose on bone remodeling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, 2006, Australia.
- Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, 2006, Australia.
- Bioengineering & Molecular Medicine Laboratory, The Children's Hospital at Westmead and the, Westmead Institute for Medical Research, Westmead, NSW, 2006, Australia.
- School of Chemical Engineering, University of New South Wales, Sydney, NSW, 2033, Australia.
- Department of Diabetes and Endocrinology, Westmead Hospital, Sydney, Australia.
- Department of Endocrinology, Royal North Shore Hospital, Sydney, Australia.
ORCID-Profile: T C Brennan-Speranza
Zitieren
APA
Shahen, V. A., Schindeler, A., Rybchyn, M. S., Girgis, C. M., Mulholland, B., Mason, R. S., Levinger, I., & Brennan-Speranza, T. C. (2023). Rescue of High Glucose Impairment of Cultured Human Osteoblasts Using Cinacalcet and Parathyroid Hormone. Calcified Tissue International. https://doi.org/10.1007/s00223-023-01062-7
Vancouver
Shahen VA, Schindeler A, Rybchyn MS, Girgis CM, Mulholland B, Mason RS, et al. Rescue of High Glucose Impairment of Cultured Human Osteoblasts Using Cinacalcet and Parathyroid Hormone. Calcified Tissue International. 2023. doi:10.1007/s00223-023-01062-7
BibTeX
@article{Shahen2023,
author = {Shahen, V A and Schindeler, A and Rybchyn, M S and Girgis, C M and Mulholland, B and Mason, R S and Levinger, I and Brennan-Speranza, T C},
title = {Rescue of High Glucose Impairment of Cultured Human Osteoblasts Using Cinacalcet and Parathyroid Hormone},
journal = {Calcified Tissue International},
year = {2023},
doi = {10.1007/s00223-023-01062-7}
}
EUVIMED